Why Healthcare ETFs Are Hovering Around One-Year Highs

Zacks
Abrir em Zacks
Why Healthcare ETFs Are Hovering Around One-Year Highs

Healthcare ETFs are hovering around one-year highs because the sector is benefiting from a solid combination of improving earnings visibility, upbeat clinical results, attractive relative valuations, and a rotation out of overcrowded AI/tech trades into defensive growth.

After years of underperformance, the sector has brightened up over the past month. State Street Health Care Select Sector SPDR ETF XLV has surged 6.4% over the past month compared with flat returns seen in State Street SPDR S&P 500 ETF Trust SPY.

SPY has returned about 9.2% over the past six months, while XLV has added 23.2% during the same timeframe (as of Oct. 20, 2026).

Inside the Rally

Earnings Acceleration

S&P 500 healthcare companies are expected to deliver double-digit earnings growth from fourth-quarter 2026 through 2027, a sharp turnaround after years of underperformance. This forward profitability upgrade is drawing fresh institutional flows, per Reuters.

Improving Margins

J.P. Morgan analysts noted in early August thatafter lagging in early 2026, healthcare now offers “durable growth, technology-like profitability, attractive valuation and diversification benefits” compared with the AI-heavy market leadership, as quoted on Reuters.

Solid Dealmaking

M&A activity is surging. M&A value in the sector has touched nearly $284 billion this year, according to Dealogic, approaching 2025's total of $306 billion and topping every other year since 2021, as quoted on Reuters in August.

Pharma Stocks Entered H2 2026 On Firmer Footing

Large pharmaceutical companies entered the second half of 2026 on much firmer footing than they were a year ago. Concerns over tariffs and U.S. drug pricing policies have eased considerably, allowing investors to shift their focus back to company fundamentals.

Meanwhile, despite continued leadership changes at the Food and Drug Administration (FDA), drug approvals have remained healthy, with early indications pointing to a more flexible regulatory environment, per a Janus Henderson report.

Major Clinical Data Releases in 2026

Personalized mRNA cancer vaccine — Moderna and Merck: Their personalized mRNA vaccine, combined with Keytruda, met trial goals for reducing melanoma recurrence and preventing cancer spread compared with Keytruda alone. It could create a new oncology growth opportunity, although overall-survival data remain outstanding.

Retatrutide — Eli Lilly: In the TRIUMPH-1 trial, participants receiving the 12-mg dose lost an average of 28.3% of their body weight over 80 weeks. The results strengthen Lilly's potential position in next-generation obesity treatments.

Tezspire — Amgen and AstraZeneca Positive Phase 3:  Amgen and AstraZeneca reported significant improvements in eosinophilic esophagitis, with sustained symptom relief and histologic remission through 52 weeks, potentially expanding Tezspire’s market beyond severe asthma.

Povetacicept — Vertex Pharmaceuticals: In the RAINIER trial, povetacicept reduced proteinuria by 49.8% versus placebo at Week 36, meeting the primary endpoint. The findings support its potential as a treatment for IgA nephropathy, a kidney disease that can progress to kidney failure.

Imdelltra plus Imfinzi — Amgen and AstraZeneca:The DeLLphi-305 trial showed a statistically significant and clinically meaningful overall-survival benefit when Imdelltra was added to Imfinzi for first-line maintenance treatment. The trial also met secondary progression-free survival and response-rate endpoints.

Bezuclastinib combination — Cogent Biosciences: The PEAK trial reported median progression-free survival of 16.5 months with bezuclastinib plus sunitinib versus 9.2 months with sunitinib alone. The results offer a potential treatment advance for patients with gastrointestinal stromal tumors previously treated with imatinib.

Encouraging Developments in the GLP-1 Market

Novo Nordisk's CagriSema delivered 25% average weight loss at 68 weeks among adult women in a new analysis conducted after a late-stage trial, with significant results across menopause statuses, potentially outperforming Wegovy, as quoted on CNBC.

CagriSema combines semaglutide, the active ingredient in Novo Nordisk’s Wegovy and Ozempic, with cagrilintide, which targets the amylin pathway to regulate hunger and fullness. The drug is expected to be launched in early 2027.

According to J.P. Morgan, only about 2% of the global obese population and 7% of diabetes patients currently receive GLP-1 treatments. Meanwhile, Gallup’s article published in mid-2026 found that the share of U.S. adults currently using GLP-1 medications for weight loss rose from 3% in 2024 to 11% in 2026. Together, these figures underscore the drug segment’s growth potential as treatment adoption expands.

ETFs in Focus

Against this backdrop, we have highlighted a few healthcare ETFs that have been hovering around a 52-week high lately.

Vaneck Biotech ETF BBH – Up 30.8% year to date (as of Oct. 20, 2026)

Invesco Biotechnology & Genome ETF PBE – Up 20.5% YTD

Global Healthcare iShares ETF IXJ – Up 11.6% YTD

US Healthcare Providers iShares ETF IHF – Up 24.7% YTD

S&P 500 Healthcare Sector SPDR XLV – Up 15.7% YTD


 

Boost Your Portfolio with Our Top ETF Insights

Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.

Don’t miss out on this valuable resource. It’s free!

Get it now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research